Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways

Neurobiology of Aging

Volumn 35, Issue 3, 2014, Pages 537-547

  Giuliani, Daniela ^a   Bitto, Alessandra ^b   Galantucci, Maria ^a   Zaffe, Davide ^a   Ottani, Alessandra ^a   Irrera, Natasha ^b   Neri, Laura ^a   Cavallini, Gian Maria ^a   Altavilla, Domenica ^b   Botticelli, Annibale R ^c   Squadrito, Francesco ^b   Guarini, Salvatore ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Alzheimer's disease; Learning and memory; Melanocortins; Neuroprotection; Pathophysiological pathways; Triple transgenic mice

Indexed keywords

AFAMELANOTIDE; AMYLOID PROTEIN; MALONALDEHYDE; MELANOCORTIN 4 RECEPTOR; NITRITE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN CORTEX; COGNITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; HIPPOCAMPUS; HISTOLOGY; INFLAMMATION; MALE; MOUSE; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; SPATIAL LEARNING; SPATIAL MEMORY; SYNAPSE; TRANSGENE; TRANSGENIC MOUSE; WESTERN BLOTTING; ZIF268 GENE;

ALZHEIMER'S DISEASE; LEARNING AND MEMORY; MELANOCORTINS; NEUROPROTECTION; PATHOPHYSIOLOGICAL PATHWAYS; TRIPLE-TRANSGENIC MICE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MALE; MELANOCORTINS; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RECEPTOR, MELANOCORTIN, TYPE 4; TAU PROTEINS;

EID: 84889586854     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.08.030     Document Type: Article

References (70)

1. Anderson B. Is alpha-MSH deficiency the cause of Alzheimer's disease?. Med. Hypoth 1986, 19:379-385.
2. Arai H., Moroji T., Kosaka K., Iizuka R. Extrahypophyseal distribution of α-melanocyte stimulating hormone (α-MSH)-like immunoreactivity in postmortem brains from normal subjects and Alzheimer-type dementia patients. Brain Res 1986, 377:305-310.
3. Bagheri M., Joghataei M.T., Mohseni S., Roghani M. Genistein ameliorates learning and memory deficits in amyloid β(1-40) rat model of Alzheimer's disease. Neurobiol. Learn. Mem 2011, 95:270-276.
4. Banerjee R., Beal M.F., Thomas B. Autophagy in neurodegenerative disorders: pathogenetic roles and therapeutic implications. Trends Neurosci 2010, 33:541-549.
5. Banks W.A., Kastin A.J. Permeability of the blood-brain barrier to melanocortins. Peptides 1995, 16:1157-1161.
6. Beug S.T., Cheung H.H., Lacasse E.C., Korneluk R.G. Modulation of immune signaling by inhibitors of apoptosis. Trends Immunol 2012, 33:535-545.
7. Bharne A.P., Upadhya M.A., Kokare D.M., Subhedar N.K. Effect of alpha-melanocyte stimulating hormone on locomotor recovery following spinal cord injury in mice: role of serotonergic system. Neuropeptides 2011, 45:25-31.
8. Bitto A., Polito F., Irrera N., Calò M., Spaccapelo L., Marini H.R., Giuliani D., Ottani A., Rinaldi M., Minutoli L., Guarini S., Squadrito F., Altavilla D. Protective effects of melanocortins on short-term changes in a rat model of traumatic brain injury. Crit. Care Med 2012, 40:945-951.
9. Blennow K. Biomarkers in Alzheimer's disease drug development. Nat. Med 2010, 16:1218-1222.
10. Brzoska T., Luger T.A., Maaser C., Abel C., Böhm M. α-Melanocyte-stimulating hormone and related tripeptides: Biochemistry, antiinflammatory and protective effects invitro and invivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr. Rev 2008, 29:581-602.
11. Caruso C., Carniglia L., Durand D., Gonzalez P.V., Scimonelli T.N., Lasaga M. Melanocortin 4 receptor activation induces brain-derived neurotrophic factor expression in rat astrocytes through cyclic AMP-protein kinase A pathway. Mol. Cell. Endocrinol 2012, 348:47-54.
12. Catania A., Gatti S., Colombo G., Lipton J.M. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol. Rev 2004, 56:1-29.
13. Chang K.A., Kim H.S., Ha T.Y., Ha J.W., Shin K.Y., Jeong Y.H., Lee J.P., Park C.H., Kim S., Baik T.K., Suh Y.H. Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol. Cell. Biol 2006, 26:4327-4338.
14. Chen G., Frøkiær J., Pedersen M., Nielsen S., Si Z., Pang Q., Stødkilde-Jørgensen H. Reduction of ischemic stroke in rat brain by alpha melanocyte stimulating hormone. Neuropeptides 2008, 42:331-338.
15. Corander M.P., Fenech M., Coll A.P. Science of self-preservation: how melanocortin action in the brain modulates body weight, blood pressure and ischemic damage. Circulation 2009, 120:2260-2268.
16. Craig-Schapiro R., Fagan A.M., Holtzman D.M. Biomarkers of Alzheimer's disease. Neurobiol. Dis 2009, 35:128-140.
17. D'Amelio M., Cavallucci V., Middei S., Marchetti C., Pacioni S., Ferri A., Diamantini A., De Zio D., Carrara P., Battistini L., Moreno S., Bacci A., Ammassari-Teule M., Marie H., Cecconi F. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat. Neurosci 2011, 14:69-76.
18. Facchinetti F., Nappi G., Petraglia F., Martignoni E., Sinforiani E., Genazzani A.R. Central ACTH deficit in degenerative and vascular dementia. Life Sci 1984, 35:1691-1697.
19. Friedlander R.M. Apoptosis and caspases in neurodegenerative diseases. N.Engl. J. Med 2003, 348:1365-1375.
20. Galimberti D., Baron P., Meda L., Prat E., Scarpini E., Delgado R., Catania A., Lipton J.M., Scarlato G. α-MSH peptides inhibit production of nitric oxide and tumor necrosis factor-α by microglial cells activated with beta-amyloid and interferon gamma. Biochem. Biophys. Res. Commun 1999, 263:251-256.
21. Galimberti D., Ghezzi L., Scarpini E. Immunotherapy against amyloid pathology in Alzheimer's disease. J.Neurol. Sci 2013, 10.1016/j.jns.2012.12.013.
22. Gao H.M., Zhou H., Hong J.S. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol. Sci 2012, 33:295-303.
23. Gatti S., Lonati C., Acerbi F., Sordi A., Leonardi P., Carlin A., Gaini S.M., Catania A. Protective action of NDP-MSH in experimental subarachnoid hemorrhage. Exp. Neurol 2012, 234:230-238.
24. Ghosh S., Wu M.D., Shaftel S.S., Kyrkanides S., LaFerla F.M., Olschowka J.A., O'Banion M.K. Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J.Neurosci 2013, 33:5053-5064.
25. Giuliani D., Minutoli L., Ottani A., Spaccapelo L., Bitto A., Galantucci M., Altavilla D., Squadrito F., Guarini S. Melanocortins as potential therapeutic agents in severe hypoxic conditions. Front. Neuroendocrinol 2012, 33:179-193.
26. Giuliani D., Mioni C., Altavilla D., Leone S., Bazzani C., Minutoli L., Bitto A., Cainazzo M.M., Marini H., Zaffe D., Botticelli A.R., Pizzala R., Savio M., Necchi D., Schiöth H.B., Bertolini A., Squadrito F., Guarini S. Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. Endocrinology 2006, 147:1126-1135.
27. 4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage. Br. J. Pharmacol 2007, 150:595-603.
28. Giuliani D., Ottani A., Minutoli L., Di Stefano V., Galantucci M., Bitto A., Zaffe D., Altavilla D., Botticelli A.R., Squadrito F., Guarini S. Functional recovery after delayed treatment of ischemic stroke with melanocortins is associated with overexpression of the activity-dependent gene Zif268. Brain Behav. Immun 2009, 23:844-850.
29. Giuliani D., Ottani A., Mioni C., Bazzani C., Galantucci M., Minutoli L., Bitto A., Zaffe D., Botticelli A.R., Squadrito F., Guarini S. Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins. Eur. J. Pharmacol 2007, 570:57-65.
30. Giuliani D., Ottani A., Zaffe D., Galantucci M., Strinati F., Lodi R., Guarini S. Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms. Neurobiol. Learn. Mem 2013, 104:82-91.
31. 4 receptors induces marked neurogenesis and long-lasting functional recovery. Acta Neuropathol 2011, 122:443-453.
32. Glat M.J., Offen D. Cell and gene therapy in Alzheimer's disease. Stem Cells Dev 2013, 22:1490-1496.
33. Grieco P., Carotenuto A., Auriemma L., Limatola A., Di Maro S., Merlino F., Mangoni M.L., Luca V., Di Grazia A., Gatti S., Campiglia P., Gomez-Monterrey I., Novellino E., Catania A. Novel α-MSH peptide analogues with broad spectrum antimicrobial activity. PLoS One 2013, 8:e61614.
34. Gustavsson A., Svensson M., Jacobi F., Allgulander C., Alonso J., Beghi E., Dodel R., Ekman M., Faravelli C., Fratiglioni L., Gannon B., Jones D.H., Jennum P., Jordanova A., Jönsson L., Karampampa K., Knapp M., Kobelt G., Kurth T., Lieb R., Linde M., Ljungcrantz C., Maercker A., Melin B., Moscarelli M., Musayev A., Norwood F., Preisig M., Pugliatti M., Rehm J., Salvador-Carulla L., Schlehofer B., Simon R., Steinhausen H.C., Stovner L.J., Vallat J.M., denBergh P.V., van Os J., Vos P., Xu W., Wittchen H.U., Jönsson B., Olesen J. Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol 2011, 21:718-779. CDBE2010Study Group.
35. Hanisch K., Soininen H., Alafuzoff I., Hoffmann R. Analysis of human tau in cerebrospinal fluid. J.Proteome Res 2010, 9:1476-1482.
36. Huang Q., Tatro J.B. α-Melanocyte stimulating hormone suppresses intracerebral tumor necrosis factor-α and interleukin-1β gene expression following transient cerebral ischemia in mice. Neurosci. Lett 2002, 334:186-190.
37. Iqbal K., Grundke-Iqbal I. Alzheimer's disease, a multifactorial disorder seeking multitherapies. Alzheimers Dement 2010, 6:420-424.
38. Iqbal K., Grundke-Iqbal I. Opportunities and challenges in developing Alzheimer disease therapeutics. Acta Neuropathol 2011, 122:543-549.
39. Ittner L.M., Götz J. Amyloid-β and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci 2011, 12:65-72.
40. Jakovcevski M., Akbarian S. Epigenetic mechanisms in neurological disease. Nat. Med 2012, 18:1194-1204.
41. Karbowski M., Neutzner A. Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathol 2012, 123:157-171.
42. Kumar S., Wirths O., Theil S., Gerth J., Bayer T.A., Walter J. Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer's disease. Acta Neuropathol 2013, 125:699-709.
43. Lo E.H. Degeneration and repair in central nervous system disease. Nat. Med 2010, 16:1205-1209.
44. Minutoli L., Bitto A., Squadrito F., Irrera N., Rinaldi M., Nicotina P.A., Arena S., Magno C., Marini H., Spaccapelo L., Ottani A., Giuliani D., Romeo C., Guarini S., Antonuccio P., Altavilla D. Melanocortin 4 receptor activation protects against testicular ischemia-reperfusion injury by triggering the cholinergic antinflammatory pathway. Endocrinology 2011, 152:3852-3861.
45. Mountjoy K.G. Distribution and function of melanocortin receptors within the brain. Adv. Exp. Med. Biol 2010, 681:29-48.
46. Munoz L., Ammit A.J. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 2010, 58:561-568.
47. Nagahara A.H., Tuszynski M.H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov 2011, 10:209-219.
48. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 2003, 39:409-421.
49. Ottani A., Giuliani D., Mioni C., Galantucci M., Minutoli L., Bitto A., Altavilla D., Zaffe D., Botticelli A.R., Squadrito F., Guarini S. Vagus nerve mediates the protective effects of melanocortins against cerebral and systemic damage after ischemic stroke. J.Cereb. Blood Flow Metab 2009, 29:512-523.
50. Rainero I., May C., Kaye J.A., Friedland R.P., Rapoport S.I. CSF α-MSH in dementia of the Alzheimer type. Neurology 1988, 38:1281-1284.
51. Salkovic-Petrisic M., Osmanovic-Barilar J., Brückner M.K., Hoyer S., Arendt T., Riederer P. Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. J.Neural Transm 2011, 118:765-772.
52. Sanchez P.E., Zhu L., Verret L., Vossel K.A., Orr A.G., Cirrito J.R., Devidze N., Ho K., Yu G.Q., Palop J.J., Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc. Natl. Acad. Sci. U.S.A 2012, 109:E2895-E2903.
53. Savos A.V., Gee J.M., Zierath D., Becker K.J. α-MSH: a potential neuroprotective and immunomodulatory agent for the treatment of stroke. J.Cereb. Blood Flow Metab 2011, 31:606-613.
54. Schellenberg G.D., Montine T.J. The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol 2012, 124:305-323.
55. Schiöth H.B., Craft S., Brooks S.J., Frey W.H., Benedict C. Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol. Neurobiol 2012, 46:4-10.
56. Sharma H.S., Skottner A., Lundstedt T., Flärdh M., Wiklund L. Neuroprotective effects of melanocortins in experimental spinal cord injury. An experimental study in the rat using topical application of compounds with varying affinity to melanocortin receptors. J.Neural Transm 2006, 113:463-476.
57. Sivak J.M. The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease. Invest. Ophthalmol. Vis. Sci 2013, 54:871-880.
58. Sivanandam T.M., Thakur M.K. Traumatic brain injury: a risk factor for Alzheimer's disease. Neurosci. Biobehav. Rev 2012, 36:1376-1381.
59. 4 receptor agonists counteract late inflammatory and apoptotic responses and improve neuronal functionality after cerebral ischemia. Eur. J. Pharmacol 2011, 670:479-486.
60. Spaccapelo L., Galantucci M., Neri L., Contri M., Pizzala R., D'Amico R., Ottani A., Zaffe D., Giuliani D., Guarini S. Up-regulation of the canonical Wnt-3A and Sonic hedgehog signaling underlies melanocortin-induced neurogenesis after cerebral ischemia. Eur. J. Pharmacol 2013, 707:78-86.
61. Sperling R.A., Karlawish J., Johnson K.A. Preclinical Alzheimer disease-the challenges ahead. Nat. Rev. Neurol 2013, 9:54-58.
62. Sy M., Kitazawa M., Medeiros R., Whitman L., Cheng D., Lane T.E., Laferla F.M. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am. J. Pathol 2011, 178:2811-2822.
63. Tashiro A., Makino H., Gage F.H. Experience-specific functional modification of the dentate gyrus through adult neurogenesis: a critical period during an immature stage. J.Neurosci 2007, 27:3252-3259.
64. Tayeb H.O., Yang H.D., Price B.H., Tarazi F.I. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol. Ther 2012, 134:8-25.
65. Vergoni A.V., Bertolini A. Role of melanocortins in the central control of feeding. Eur. J. Pharmacol 2000, 405:25-32.
66. Wang J.M., Singh C., Liu L., Irwin R.W., Chen S., Chung E.J., Thompson R.F., Brinton R.D. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 2010, 107:6498-6503.
67. Wikberg J.E., Mutulis F. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nat. Rev. Drug Discov 2008, 7:307-323.
68. Wolfe M.S. Tau mutations in neurodegenerative diseases. J.Biol. Chem 2009, 284:6021-6025.
69. Yu Y., Run X., Liang Z., Li Y., Liu F., Liu Y., Iqbal K., Grundke-Iqbal I., Gong C.X. Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J.Neurochem 2009, 108:1480-1494.
70. Zipp F., Aktas O. The brain as a target of inflammation: common pathways link inflammatory and nurodegenerative diseases. Trends Neurosci 2006, 29:518-527.